Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05800574 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 22, 2026 (before its estimated September 23, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 23, 2025 to Sep 23, 2026v5
  2. Primary completion date: Sep 23, 2024 to Sep 23, 2025
    • Study completion date: Sep 23, 2026 to Sep 23, 2027
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 3 of 7 entries
    • Study description expanded, about 16 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
Trial Details
NCT Number NCT05800574
Lead Sponsor Fox Chase Cancer Center
Collaborators: Cardinal Health
Conditions
(from sponsor)		 Oropharynx Cancer
Related terms Oropharyngeal Neoplasms
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov